Year: 2026
Type: article
Abstract: HPV-positive OPSCC shows a favourable prognosis, prompting evaluation of de-escalated and adaptive strategies. Quantitative imaging may provide scalable biomarkers to individualise care. Quantitative imaging can support baseline risk stratification, early on-treatment decision-making, and posttreatment surveillance in HPV-positive OPSCC. Real-world translation requires standardised reporting, calibration/harmonisation across centres, rigorous model validation, and workflow integration with radiotherapy planning. Quantitative MRI, CT, and PET, augmented by radiomics and AI, show convergent promise as non-invasive biomarkers to enable safe individualisation of therapy in HPV-positive OPSCC, contingent on methodological rigour and prospective, externally validated studies. Despite this promise, clinical translation faces substantial barriers, including limited external validation, heterogeneous methodologies, and the need for standardised, prospectively validated pipelines.
Source: Cancers
Institutions: Austin Hospital, Austin Health, Centre Hospitalier de l’Université de Montréal, Universidade de São Paulo, Hospital Israelita Albert Einstein, AC Camargo Hospital, University Medical Center Utrecht, University of Michigan, Universitair Ziekenhuis Leuven, KU Leuven, Hospital Universitario Central de Asturias, Sri Shankara Cancer Hospital and Research Center, Jena University Hospital, Universidad de Oviedo, Instituto de Investigación Sanitaria del Principado de Asturias, Emory University, Winship Cancer Institute
Language: English
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,499
OpenAlex ID: W7124833785